Denka Markova

2.6k total citations · 1 hit paper
18 papers, 1.7k citations indexed

About

Denka Markova is a scholar working on Surgery, Oncology and Genetics. According to data from OpenAlex, Denka Markova has authored 18 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Surgery, 7 papers in Oncology and 7 papers in Genetics. Recurrent topics in Denka Markova's work include Thyroid and Parathyroid Surgery (6 papers), BRCA gene mutations in cancer (5 papers) and PARP inhibition in cancer therapy (5 papers). Denka Markova is often cited by papers focused on Thyroid and Parathyroid Surgery (6 papers), BRCA gene mutations in cancer (5 papers) and PARP inhibition in cancer therapy (5 papers). Denka Markova collaborates with scholars based in United States, Germany and Spain. Denka Markova's co-authors include Sara A. Hurvitz, Rinat Yerushalmi, Jennifer K. Litton, Hope S. Rugo, Anthony Gonçalvès, Johannes Ettl, W. Eiermann, Henri Roché, Alison L. Hannah and Lida A. Mina and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Denka Markova

18 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

2018 1.4k citations Jennifer K. Litton, Hope S. Rugo et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Denka Markova United States	8	1.2k	633	520	485	420	18	1.7k
Filipa Lynce United States	21	1.3k 1.0×	571 0.9×	456 0.9×	323 0.7×	474 1.1×	110	1.9k
Antonello Abbattista Italy	21	1.5k 1.2×	716 1.1×	1.4k 2.7×	99 0.2×	479 1.1×	46	2.2k
Elena Castro Spain	22	1.1k 0.9×	876 1.4×	1.8k 3.5×	482 1.0×	729 1.7×	116	2.8k
Payal D. Shah United States	20	478 0.4×	288 0.5×	190 0.4×	244 0.5×	190 0.5×	72	1.0k
Annabel Goodwin Australia	18	722 0.6×	256 0.4×	330 0.6×	281 0.6×	396 0.9×	45	1.1k
Edward D. Esplin United States	22	522 0.4×	866 1.4×	349 0.7×	789 1.6×	539 1.3×	118	2.0k
Matthew Maurer United States	20	824 0.7×	625 1.0×	216 0.4×	109 0.2×	233 0.6×	54	1.4k
Noah Berkowitz United States	18	466 0.4×	452 0.7×	386 0.7×	254 0.5×	101 0.2×	41	1.8k
Stéphane Vignot France	16	686 0.6×	630 1.0×	391 0.8×	115 0.2×	469 1.1×	91	1.7k
Lisa Wiechmann United States	13	538 0.4×	430 0.7×	416 0.8×	168 0.3×	226 0.5×	24	1.3k

Countries citing papers authored by Denka Markova

Since Specialization

Citations

This map shows the geographic impact of Denka Markova's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Denka Markova with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Denka Markova more than expected).

Fields of papers citing papers by Denka Markova

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Denka Markova. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Denka Markova. The network helps show where Denka Markova may publish in the future.

Co-authorship network of co-authors of Denka Markova

This figure shows the co-authorship network connecting the top 25 collaborators of Denka Markova. A scholar is included among the top collaborators of Denka Markova based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Denka Markova. Denka Markova is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Ahmed, Intekhab, Erik Fink Eriksen, Lorenz C. Hofbauer, et al.. (2022). OR21-1 The PaTH Forward Trial: Efficacy and Safety of TransCon PTH Through Week 84 for Adults With Hypoparathyroidism. Journal of the Endocrine Society. 6(Supplement_1). A193–A193. 2 indexed citations

Palermo, Andrea, Tamara Vokes, Aliya Khan, et al.. (2022). Health related quality of life in adults with hypoparathyroidism in an exploratory analysis of the phase 2 PaTH forward trial of TransCon PTH. Endocrine Abstracts. 1 indexed citations

Brod, Meryl, Lori McLeod, Denka Markova, et al.. (2021). Psychometric validation of the Hypoparathyroidism Patient Experience Scales (HPES). Journal of Patient-Reported Outcomes. 5(1). 70–70. 10 indexed citations

Khan, Aliya, Lars Rejnmark, Mishaela R. Rubin, et al.. (2021). PaTH Forward: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of TransCon PTH in Adult Hypoparathyroidism. The Journal of Clinical Endocrinology & Metabolism. 107(1). e372–e385. 28 indexed citations

Karpf, David, et al.. (2020). A Randomized Double-Blind Placebo-Controlled First-In-Human Phase 1 Trial of TransCon PTH in Healthy Adults. Journal of Bone and Mineral Research. 35(8). 1430–1440. 31 indexed citations

Khan, Aliya, Lars Rejnmark, Peter Schwarz, et al.. (2020). SAT-LB72 Design of the PaTH Forward Phase 2 Trial of TransCon PTH, a Long-Acting PTH, in Patients With Hypoparathyroidism. Journal of the Endocrine Society. 4(Supplement_1). 3 indexed citations

Litton, Jennifer K., Hope S. Rugo, Johannes Ettl, et al.. (2018). Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. New England Journal of Medicine. 379(8). 753–763. 1401 indexed citations breakdown →

Ettl, Johannes, Ruben G.W. Quek, Ki Hoon Lee, et al.. (2018). Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Annals of Oncology. 29(9). 1939–1947. 106 indexed citations

Rugo, Hope S., Johannes Ettl, Natasha Woodward, et al.. (2018). EMBRACA: Efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of therapy (PCT) in patients with advanced breast cancer and a germline BRCA mutation.. Journal of Clinical Oncology. 36(15_suppl). 1069–1069. 4 indexed citations

10.

Eiermann, W., Hope S. Rugo, Sami Diab, et al.. (2018). Analysis of germline BRCA1/2 mutated (gBRCA^mut) hormone receptor-positive (HR+) and triple negative breast cancer (TNBC) treated with talazoparib (TALA).. Journal of Clinical Oncology. 36(15_suppl). 1070–1070. 9 indexed citations

11.

Martín, Miguel, W. Eiermann, Hope S. Rugo, et al.. (2018). EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment. Annals of Oncology. 29. viii96–viii96. 2 indexed citations

12.

Elias, AD, et al.. (2016). Abstract P1-16-05: MDV3100-08: A phase 1 study evaluating the safety and pharmacokinetics of enzalutamide plus fulvestrant in women with advanced hormone receptor-positive breast cancer. Cancer Research. 76(4_Supplement). P1–16. 7 indexed citations

13.

Anderson, A., Denka Markova, Tyson H. Holmes, et al.. (2015). Bupropion for the treatment of methamphetamine dependence in non-daily users: A randomized, double-blind, placebo-controlled trial. Drug and Alcohol Dependence. 150. 170–174. 49 indexed citations

14.

Elkins, Gary, et al.. (2010). Perceived Stress Among Nursing and Administration Staff Related to Accreditation. Clinical Nursing Research. 19(4). 376–386. 36 indexed citations

15.

Markova, Denka, et al.. (2009). [Ovarian cancer with metastatic lesion in the vagina (foetus papiraceus)].. PubMed. 48(3). 49–51. 1 indexed citations

16.

Markova, Denka, et al.. (2009). [Immunohistochemical profile of colorectal and ovarian carcinomas--examination with cytokeratin 7, cytokeratin 20, beta catenin and cDX 2].. PubMed. 48(2). 7–12. 3 indexed citations

17.

Markova, Denka, et al.. (2008). [Role of total inhibin in diagnosis and monitoring of ovarian cancer in postmenopausal women].. PubMed. 47(1). 16–9. 1 indexed citations

18.

Shipkov, Hristo, et al.. (2000). Pleural effusions in acute pancreatitis.. PubMed. 42(3). 34–6. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact